Tag: Seattle Genetics

Nearly 7 years ago, in 2009, Seattle Genetics, a clinical stage biopharmaceutical company, and Takeda Pharmaceuticals, Japan's largest pharmaceutical company with a 230+ year...

Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy.  Oral...

Earlier today Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer,  confirmed that...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

A study published in the September 16, 2015 online edition of Blood, the Journal of the American Society of Hematology (ASH), reports that brentuximab...

A new phase II clinical trial designed to evaluate the safety and efficacy of brentuximab vedotin (Adcetris®; Seattle Genetics) in systemic lupus erythematosus also known...

Seattle Genetics and Unum Therapeutics have entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer...

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA setting...

Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...

Earlier today, Seattle Genetics Inc, announced the initiation of a new Phase I clinical trial of SEA-CD40, which utilizes the company's proprietary Sugar-Engineered Antibody technology...